Margaret Koziel - Dec 1, 2021 Form 3 Insider Report for Axcella Health Inc. (AXLA)

Role
Chief Medical Officer
Signature
/s/ Paul Fehlner, Attorney-in-Fact
Stock symbol
AXLA
Transactions as of
Dec 1, 2021
Transactions value $
$0
Form type
3
Date filed
12/13/2021, 04:55 PM
Next filing
Dec 13, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AXLA Common Stock 30K Dec 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AXLA Stock Option (Right to Buy) Dec 1, 2021 Common Stock 20.8K $9.31 Direct F2
holding AXLA Stock Option (Right to Buy) Dec 1, 2021 Common Stock 10.3K $4.12 Direct F3
holding AXLA Stock Option (Right to Buy) Dec 1, 2021 Common Stock 11K $5.04 Direct F4
holding AXLA Stock Option (Right to Buy) Dec 1, 2021 Common Stock 31.1K $6.59 Direct F5
holding AXLA Stock Option (Right to Buy) Dec 1, 2021 Common Stock 10K $4.11 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of 30,000 Restricted Stock Units ("RSUs"), each representing a contingent right to receive one share of AXLA common stock. 25% of the shares underlying this grant vested on August 31, 2021, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2 25% of the shares underlying this option vested and became exercisable on June 27, 2020, with the remainder vesting in twelve equal quarterly installments thereafter, subject to subject to Reporting Person's continued service on each such vesting date.
F3 25% of the shares underlying this option vested and became exercisable on January 2, 2021, with the remainder vesting in twelve equal quarterly installments thereafter, subject to subject to Reporting Person's continued service on each such vesting date.
F4 25% of the shares underlying this option vested and became exercisable on November 10, 2021, with the remainder vesting in twelve equal quarterly installments thereafter, subject to subject to Reporting Person's continued service on each such vesting date.
F5 25% of the shares underlying this option shall vest and become exercisable on February 9, 2022, with the remainder vesting in twelve equal quarterly installments thereafter, subject to subject to Reporting Person's continued service on each such vesting date.
F6 25% of the shares underlying this option shall vest and become exercisable on June 25, 2022, with the remainder vesting in twelve equal quarterly installments thereafter, subject to subject to Reporting Person's continued service on each such vesting date

Remarks:

Exhibit 24 - Power of Attorney